What it sells
Oral drugs to halt neurodegeneration
Business model breakdown
Buyer: who owns the budget?
UnverifiedPharma partners/acquirers and investors; patients indirectly.
Workflow: what inputs become what output?
Discovers oral small-molecule protein degraders and conformation correctors for neurodegenerative diseases using the ORICISION platform and patient-derived disease models.
Economics: what it saves and how it charges
UnverifiedPre-revenue biotech; value comes from advancing a drug pipeline (likely licensing/partnering or equity funding).
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| — | Y Combinator Winter 2022 | — | Y Combinator | ycombinator.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-12.